1.Shen L, Peng Z, et al. Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA).2024 ESMO LBA60.2.Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical...
1、GS4-10 Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. 2021 SABCS 2、Yi Z, Rong G, Guan Y,...
NGS是另一种常用的检测HER2扩增和点突变的方法,但目前尚无统一的、针对NGS检测HER2扩增的阳性判读标准。一项乳腺癌回顾性研究表明,HER2 IHC阳性(3+)的患者通过FISH检测阳性(HER2扩增)的比例为91.4%,且大部分HER2 IHC阴性(98.5%的IHC 0,93.1%的IHC 1+)乳腺...
然而,发起DESTINY-Lung 01试验的Li及其团队已将HER2突变/HER2阴性转移性BC患者纳入了正在进行的临床试验中,该试验涉及使用T-DXd治疗具有激活性HER2突变的晚期实体瘤患者的有效性和安全性(DESTINY-PanTumor01,NCT04639219)。 吡咯替尼是一种抗HER1、HER2 和HER4的不可逆泛HER酪氨酸激酶抑制剂,在HER2阳性转移性BC患者...
SAJI S, TAIRA N, KITADA M, et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial [J]. Lancet Oncol, 2022, S1470-2045(...
CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer. 2020; 10.7150/jca.48944.Lloyd M R, et al. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative ...
[7].Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 2017;28:2420–8.* 本文由阿斯利康提供支持，仅供医疗专业人士参考 审批编号：CN-106964 有效期至：2023-12-6 *此...
[4]Palmieri, Carlo et al. “Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel ...
Sara M Tolaney et al. Lancet Oncol. 2023 Mar;24(3):273-285.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial 编辑|r.G 审核|贾巍教授...
1.Berger F,Marce M,Delaloge S,et al.Randomised,open-label,multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy,guided by ESR1 mutation monitoring in oestrogen receptor-positive,HER2-negative metastatic breast cancer patients:study design...